Investors
We are committed to delivering our strategy and creating value for our shareholders.
Latest News
Latest Events
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021
Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,
Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company
Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update
ENHANCE Phase 3 program on track to report top-line data in 2022 Up to $219 million strategic collaboration with Nuance Pharma in Greater China Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA)
Discover More
Verona Pharma
Investor Information
© Verona Pharma plc 2021. All rights reserved